TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05074498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion
Study: NCT04944693

Intervention type: OTHER
Intervention: Different ATS values.
Description: Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts.

Intervention type: OTHER
Intervention: Different ATS values.
Description: Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts.
Study: NCT05037656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based curriculum
Description: Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
Study: NCT05978609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candonilimab
Description: Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
Study: NCT05805059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact Lens (stenfilcon A)
Description: one week wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact Lens (stenfilcon A)
Description: one week wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact Lens (senofilcon A)
Description: one week of wear
Study: NCT05159596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Technology System
Description: Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Limited In-Home Technology
Description: Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
Study: NCT06476275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/Texas/71/2017 (H3N2)
Description: Virus will be administered intranasally

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham placebo
Description: Placebo will be administered intranasally
Study: NCT04451590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-based simulation
Description: Participants will experience a novel interactive and immersive VR full size trauma bay with an adult patient and healthcare professionals. Immersed in the environment, learners undertake the decision-making steps in managing the medical care for a patient with an airway injury. Learners are first given the case scenario from which they form their own learning goals/plans. They then navigate through the scenario that will provide feedback depending on their actions in the form of either the patient's hemodynamic changes or prompts from healthcare avatars in the scenario. These feedback processes are built-in and designed to promote reflection and reorganization of the learner's decision-making strategies. As learning progresses, fewer prompts will be given. At the end of the scenario, evaluation algorithms pre-programmed into the VR-based simulation will be displayed.

Intervention type: OTHER
Group type: OTHER
Intervention: Mannequin-based simulation
Description: Participants will experience a mannequin-based scenario practice which is the current gold standard in medical education. The trauma airway management scenario will match the VR environment and sequence of events.
Study: NCT06637826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quaternary Ammonium Compound Disinfectants
Description: Participants are instructed to use quaternary ammonium compound disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-based Disinfectants
Description: Participants are instructed to use alcohol-based disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation.
Study: NCT05769218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHORUS+
Description: The CHORUS+ intervention will include a baseline interview with a peer recovery coach to encourage uptake of HIV PrEP (pre-exposure prophylaxis) and medications for opioid use disorder (MOUD) through motivational interviewing (MI). Participants will also be offered HIV self-testing on the day of recruitment, HIV PrEP (if they are HIV negative) and MOUD. Participants will then receive peer coaching for 6 months to increase adherence to PrEP and or MOUD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Normal protocols for care of participants who inject opioids will be followed.
Study: NCT03897075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
Study: NCT05359783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superparamagnetic Iron Oxide
Description: Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
Study: NCT05805059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact Lens (senofilcon A)
Description: one week of wear
Study: NCT05905458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950 tablets
Description: HRS9950 tablets, oral, once a week, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950 tablets
Description: HRS9950 tablets, oral, once a week, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9950 placebo tablets
Description: HRS9950 placebo tablets, oral, once a week.
Study: NCT05034185

Intervention type: DEVICE
Intervention: Computer-aided diagnosis (CADx) support tool
Description: The CADx support tool operates when the Clinician switches the preconfigured CAD EYE function on using a button on the controller while the scope system is in BLI mode. This is performed after the Clinician first makes an optical prediction of polyp histology using IEE as described. The CADx support tool will make a prediction of polyp histology as hyperplastic or neoplastic.
Study: NCT06527105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye masks and ear plugs
Description: Eye masks and ear plugs given during sleeping time in Icu After cardiac surgery
Study: NCT04203433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLX105-DMP
Description: 1mg applied to target lesion
Study: NCT04968795

Intervention type: OTHER
Intervention: Heartfulness Meditation
Description: A four-week Heartfulness Wellness seminar, where people are exposed to Heartfulness Meditation and its meditation tools. Participants experience: Heartfulness Guided Relaxation, Heartfulness Meditation and Heartfulness Unwinding/Rejuvenation Technique.
Study: NCT04502719

Intervention type: DIAGNOSTIC_TEST
Intervention: Nutritional screening.
Description: Nutritional screening with the RFH-NPT and LDUST questionnaires.
Study: NCT05247840

Intervention type: DIAGNOSTIC_TEST
Intervention: uroflowmetry
Description: Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: uroflowmetry
Description: Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.
Study: NCT05514132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
Study: NCT05247840

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic dysfunction test proposed by Ewing et al.
Description: CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic dysfunction test proposed by Ewing et al.
Description: CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
Study: NCT03897075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildrakizumab
Description: PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
Study: NCT05738148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC \[2,3\] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing.
Study: NCT05247840

Intervention type: DIAGNOSTIC_TEST
Intervention: peripheral nerve conduction test
Description: Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.

Intervention type: DIAGNOSTIC_TEST
Intervention: peripheral nerve conduction test
Description: Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
Study: NCT05835024

Intervention type: DEVICE
Intervention: Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1
Description: A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.~A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation.

Intervention type: DEVICE
Intervention: Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2
Description: A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.~No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.
Study: NCT05738148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed\[2,3\]. Chest compressions and epinephrine will be continued until ROSC.
Study: NCT05375643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SURGE
Description: Video with or without person to person guidance to support decision making around genetic testing
Study: NCT05377008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMAL-SSI
Description: The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
Study: NCT05399303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturation
Description: obturation using different types of sealers

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturation
Description: obturation using different types of sealers
Study: NCT06429618

Intervention type: DIETARY_SUPPLEMENT
Intervention: Low carbonhydrate diet
Description: Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Low carbonhydrate diet
Description: Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Low carbonhydrate diet
Description: Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Low carbonhydrate diet
Description: Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.
Study: NCT05914558

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical appointment
Description: One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
Study: NCT06391177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Oral tablet.
Study: NCT05515094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment Counseling Intervention
Description: The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
Study: NCT06279429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sideral® Sucrosomial Iron
Description: Sucrosomial Iron 30mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron chewable tablet
Description: Iron chewable tablet 100mg
Study: NCT04817254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: 150 mg/m2 on days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: 150 mg/m2 on days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab 3mg/kg
Description: 3 mg/kg q 4 weeks for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab 1mg/kg
Description: 1 mg/kg q 4 weeks for cycles 1-4